REFERENCES
1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45.
2. Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022;40:2957-95.
3. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399-410.
4. Mori K, Abufaraj M, Mostafaei H, et al. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79:783-92.
5. Lasorsa F, di Meo NA, Rutigliano M, et al. Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice. Biomedicines. 2023;11:1071.
6. Fiorentino V, Tralongo P, Larocca LM, Pizzimenti C, Martini M, Pierconti F. First-line ICIs in renal cell carcinoma. Hum Vaccin Immunother. 2023;19:2225386.
7. Napolitano L, Manfredi C, Cirillo L, et al. Cytoreductive nephrectomy and metastatic renal cell carcinoma: state of the art and future perspectives. Medicina. 2023;59:767.
8. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5:164-70.
9. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417-27.
10. Bhindi B, Habermann EB, Mason RJ, et al. Comparative survival following initial cytoreductive nephrectomy vs. initial targeted therapy for metastatic renal cell carcinoma. J Urol. 2018;200:528-34.
11. García-Perdomo HA, Zapata-Copete JA, Castillo-Cobaleda DF. Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis. Investig Clin Urol. 2018;59:2-9.
12. Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020;26:475-84.
13. Westerman ME, Shapiro DD, Wood CG, Karam JA. Neoadjuvant therapy for locally advanced renal cell carcinoma. Urol Clin North Am. 2020;47:329-43.
14. Bex A, van der Veldt AA, Blank C, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27:533-9.
15. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28:1502-7.
16. de Velasco G, Carril-Ajuria L, Guerrero-Ramos F, et al. A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. Oncotarget. 2020;11:4457-62.
17. Hatiboglu G, Hohenfellner M, Arslan A, et al. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbecks Arch Surg. 2017;402:637-44.
18. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184:859-64.
19. Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014;66:874-80.
20. Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A. Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology. 2013;81:111-5.
21. Lane BR, Derweesh IH, Kim HL, et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol. 2015;33:112.e15-21.
22. Lebacle C, Bensalah K, Bernhard JC, et al. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int. 2019;123:804-10.
23. Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187:1548-54.
24. Rini BI, Plimack ER, Takagi T, et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol. 2015;194:297-303.
25. Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106:1270-6.
26. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181:518-23; discussion 523.
27. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431-6.
28. Zhang Y, Li Y, Deng J, Ji Z, Yu H, Li H. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma. PLoS One. 2015;10:e0115896.
29. Bickley LJ, Yang YH, Jackson-Spence F, et al. Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens. World J Urol. 2024;42:442.
30. Meerveld-Eggink A, Graafland N, Wilgenhof S, et al. Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment. Eur Urol Open Sci. 2022;35:54-8.
31. Pignot G, Thiery-Vuillemin A, Albigès L, et al. Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma. Eur Urol Oncol. 2022;5:577-84.
32. Shirotake S, Miyama YU, Baba Y, et al. Impact of cytoreductive nephrectomy following nivolumab plus ipilimumab therapy for patients with advanced renal cell carcinoma. Anticancer Res. 2022;42:2727-35.
33. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab vs. sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277-90.
34. Albiges L, Tannir NM, Burotto M, et al. First-line nivolumab plus ipilimumab vs. sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol. 2022;81:266-71.
35. Shapiro DD, Karam JA, Zemp L, et al. Cytoreductive nephrectomy following immune checkpoint inhibitor therapy is safe and facilitates treatment-free intervals. Eur Urol Open Sci. 2023;50:43-6.
36. Graafland NM, Szabados B, Tanabalan C, et al. Surgical safety of deferred cytoreductive nephrectomy following pretreatment with immune checkpoint inhibitor-based dual combination therapy. Eur Urol Oncol. 2022;5:373-4.
37. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.
38. Marandino L, Campi R, Amparore D, et al. Neoadjuvant and adjuvant immune-based approach for renal cell carcinoma: pros, cons, and future directions. Eur Urol Oncol. 2025;8:494-509.
39. Bex A, Abu-Ghanem Y, Van Thienen JV, et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J Clin Oncol. 2022;40:289.
40. Au L, Hatipoglu E, Robert de Massy M, et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021;39:1497-518.e11.
41. Ghoreifi A, Vaishampayan U, Yin M, Psutka SP, Djaladat H. Immune checkpoint inhibitor therapy before nephrectomy for locally advanced and metastatic renal cell carcinoma: a review. JAMA Oncol. 2024;10:240-8.
42. Allaf ME, Kim SE, Master V, et al. Perioperative nivolumab vs. observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25:1038-52.
43. Runcie K, Singer EA, Ornstein MC, et al. Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib). J Clin Oncol. 2021;39:TPS4598.
44. Vaishampayan UN, Tangen C, Tripathi A, et al. SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer. J Clin Oncol. 2022;40:TPS402.
45. Iisager L, Ahrenfeldt J, Donskov F, et al. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. BMC Cancer. 2024;24:260.
46. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683-94.
47. Choueiri TK, Tomczak P, Park SH, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024;390:1359-71.
48. Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab vs. placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400:1103-16.
49. Ryan CW, Tangen CM, Heath EI, et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023;402:1043-51.
50. Procopio G, Apollonio G, Cognetti F, et al. Sorafenib vs. observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study. Eur Urol Oncol. 2019;2:699-707.
51. Choueiri TK, Bedke J, Karam JA, et al. LITESPARK-022: a phase 3 study of pembrolizumab plus belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2022;40:TPS4602.
52. Bedke J, Ghanem YA, Albiges L, et al. Updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma. Eur Urol. 2025;87:491-6.
53. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol. 2020;38:604.e9-17.
54. Dason S, Goradia R, Heh V, et al. Impact of preoperative systemic therapy on cytoreductive nephrectomy outcomes in the national surgical quality improvement program (NSQIP). Clin Genitourin Cancer. 2025;23:102258.
55. Reese SW, Eismann L, White C, et al. Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma. Urol Oncol. 2024;42:32.e9-16.
56. A phase III study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stage II/III non-small cell lung cancer (AEGEAN): contribution of treatment phase in perioperative trials. FDA Oncologic Drugs Advisory Committee Meeting; 2024, p. 1-6. Available from: https://www.fda.gov/media/180308/download [Last accessed on 9 Jul 2025].
57. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672-84.
58. Berry DA. Of adaptive and factorial designs: a biostatistician's interpretation of last week's ODAC. Cancer Lett. 2024;50:32-6. Available from: https://cancerletter.com/trials-and-tribulations/20240802_4/ [Last accessed on 9 Jul 2025].
59. Rossi SH, Choueiri TK, Jewett M, et al. What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An international neoadjuvant kidney cancer consortium delphi study. Ann Oncol. 2025:S0923-7534(25)00769.
60. Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the "all-around warrior" in immunotherapy. Mol Cancer. 2024;23:183.
61. Germanà E, Pepe L, Pizzimenti C, et al. Programmed cell death ligand 1 (PD-L1) immunohistochemical expression in advanced urothelial bladder carcinoma: an updated review with clinical and pathological implications. Int J Mol Sci. 2024;25:6750.
62. Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41:404-20.
63. Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55:527-41.e5.
64. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008-16.
65. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246-54.
66. Motzer RJ, Russo P, Haas N, et al. Adjuvant pazopanib vs. placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol. 2021;79:334-8.
67. Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib vs. placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29:2371-8.
68. Eisen T, Frangou E, Oza B, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol. 2020;38:4064-75.
69. Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab vs. placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401:821-32.
